NCT05899621 A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL Status RECRUITING Phase N/A
NCT05890352 Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Status RECRUITING Phase PHASE2
NCT05867030 Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma Status WITHDRAWN Phase PHASE1
NCT05861050 Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma Status RECRUITING Phase PHASE1/PHASE2
NCT05849610 Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05848765 Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy Status RECRUITING Phase PHASE2
NCT05846880 VitD3 Supplementation in Patients With Multiple Myeloma Status RECRUITING Phase EARLY_PHASE1
NCT05846750 Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma Status RECRUITING Phase PHASE2
NCT05831969 Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC Status UNKNOWN Phase PHASE2
NCT05827016 A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma Status RECRUITING Phase PHASE3
NCT05821088 Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma Status RECRUITING Phase PHASE2
NCT05820763 Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant Status WITHDRAWN Phase PHASE2
NCT05804032 Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma Status COMPLETED Phase PHASE3
NCT05802992 The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients Status UNKNOWN Phase PHASE3
NCT05797948 GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Status UNKNOWN Phase NA
NCT05788289 A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma Status TERMINATED Phase PHASE2
NCT05776979 Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients Status RECRUITING Phase PHASE2
NCT05690984 Elimination of Minimal Residual Disease After Transplant Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05690191 Chidamide in Patients With Recurrent and Refractory Diffuse Large b Status ENROLLING_BY_INVITATION Phase N/A